Novo Nordisk A S annual total debt
2019
2020
2021
2022
2023
2024
2025
Novo Nordisk A S Total Debt Growth & History (NVO)
Novo Nordisk A S's total debt was kr139.53B for fiscal 2025.
View full Novo Nordisk A S company overviewNovo Nordisk A S annual total debt history
| Fiscal year | Period ended | Total debt | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | kr139.53B | kr29.98B | +27.36% |
| 2024 | 2024-12-31 | kr109.55B | kr76.82B | +234.70% |
| 2023 | 2023-12-31 | kr32.73B | kr2.42B | +7.98% |
| 2022 | 2022-12-31 | kr30.31B | −kr461.0M | −1.50% |
| 2021 | 2021-12-31 | kr30.77B | kr16.75B | +119.38% |
| 2020 | 2020-12-31 | kr14.03B | kr5.72B | +68.87% |
| 2019 | 2019-12-31 | kr8.31B | — | — |
Novo Nordisk A S quarterly total debt
Q4.20
Q4.21
Q4.22
Q4.23
Q4.24
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Total debt | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | kr140.13B | kr40.86B | +41.16% |
| Q1 2026 | 2026-03-31 | kr146.38B | — | — |
| Q4 2025 | 2025-12-31 | kr139.53B | kr29.98B | +27.36% |
| Q3 2025 | 2025-09-30 | kr101.21B | — | — |
| Q2 2025 | 2025-06-30 | kr99.27B | — | — |
| Q4 2024 | 2024-12-31 | kr109.55B | kr76.82B | +234.70% |
| Q4 2023 | 2023-12-31 | kr32.73B | kr2.42B | +7.98% |
| Q4 2022 | 2022-12-31 | kr30.31B | −kr461.0M | −1.50% |
| Q4 2021 | 2021-12-31 | kr30.77B | kr16.75B | +119.38% |
| Q4 2020 | 2020-12-31 | kr14.03B | — | — |
Novo Nordisk A S total debt trends
Over the last five fiscal years, Novo Nordisk A S's total debt increased from kr14.03B to kr139.53B, a change of kr125.50B. The latest reported quarter, Q2 2026, shows kr140.13B.
About the metric
What total debt means
Total debt measures a company’s reported interest-bearing borrowing obligations at a reporting-period end. It can include short-term borrowings, current maturities, long-term debt, and finance lease obligations when they are included in the company’s debt facts.
Calculation and source
SEC-reported and combined total debt
TickerStat uses a reported aggregate debt value when available. Otherwise, it combines non-overlapping current and noncurrent debt facts from SEC filings. Total liabilities are not treated as debt, and missing debt is not assumed to be zero. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Novo Nordisk A S source filings ↗Community posts
Novo Nordisk reports positive STEP Young results in children aged 6 to under 12
Novo Nordisk announced first STEP Young Phase 3 results on 7 September 2026. Trial design and outcome The randomised, double-blind study involved 165 children aged 6 to under 12, comparing weekly semaglutide with placebo. Both groups receiv ...